Daryl Pritchard

1.2k total citations
31 papers, 863 citations indexed

About

Daryl Pritchard is a scholar working on Health, Toxicology and Mutagenesis, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Daryl Pritchard has authored 31 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Health, Toxicology and Mutagenesis, 9 papers in Economics and Econometrics and 9 papers in Cancer Research. Recurrent topics in Daryl Pritchard's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Chromium effects and bioremediation (8 papers) and Cancer Genomics and Diagnostics (8 papers). Daryl Pritchard is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Chromium effects and bioremediation (8 papers) and Cancer Genomics and Diagnostics (8 papers). Daryl Pritchard collaborates with scholars based in United States and South Korea. Daryl Pritchard's co-authors include Steven R. Patierno, Jatinder Singh, Diane L. Carlisle, Travis J. O’Brien, John A. McLean, H. George Mandel, Catherine A. McCarty, Howard L. McLeod, Jan M. Orenstein and Neal J. Meropol and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Environmental Health Perspectives.

In The Last Decade

Daryl Pritchard

29 papers receiving 830 citations

Peers

Countries citing papers authored by Daryl Pritchard

Since Specialization

Citations

This map shows the geographic impact of Daryl Pritchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daryl Pritchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daryl Pritchard more than expected).

Fields of papers citing papers by Daryl Pritchard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daryl Pritchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daryl Pritchard. The network helps show where Daryl Pritchard may publish in the future.

Co-authorship network of co-authors of Daryl Pritchard

This figure shows the co-authorship network connecting the top 25 collaborators of Daryl Pritchard. A scholar is included among the top collaborators of Daryl Pritchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daryl Pritchard. Daryl Pritchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimization of oncology biomarker testing in managed care: Best practices and consensus recommendations from an AMCP Market Insights program 2025 ·Journal of Managed Care & Specialty Pharmacy ·Diana Brixner, (unknown), (unknown), Scott D. Ramsey, John P. Fox, Daryl Pritchard, Howard L. McLeod, (unknown), (unknown), (unknown)	0
2	Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine 2024 ·Journal of Personalized Medicine ·(unknown), Daryl Pritchard, (unknown), (unknown), Thomas D. Brown, (unknown)	0
3	Perspectives on clinical adoption barriers to blood-based multi-cancer early detection tests across stakeholders. 2024 ·Journal of Clinical Oncology ·Monica M. Schroll, (unknown), Daryl Pritchard, (unknown), (unknown), Omar Perez, (unknown), (unknown)	1
4	Perspectives on Clinical Adoption Barriers to Blood-Based Multi-Cancer Early Detection Tests across Stakeholders 2024 ·Journal of Personalized Medicine ·Monica M. Schroll, (unknown), Daryl Pritchard, (unknown), (unknown), Omar Perez, (unknown), (unknown)	4
5	Stakeholders Perceptions of Barriers to Precision Medicine Adoption in the United States 2022 ·Journal of Personalized Medicine ·Monica M. Schroll, (unknown), (unknown), (unknown), Omar Perez, Daryl Pritchard, (unknown), (unknown), (unknown)	6
6	Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer 2022 ·JCO Precision Oncology ·Helen Sadik, Daryl Pritchard, (unknown), (unknown), Peter V. Riccelli, (unknown), (unknown), (unknown), (unknown)	56
7	The Integration of Personalized Medicine Into Health Systems: Progress and a Path Forward 2021 ·Personalized Medicine ·Daryl Pritchard, Peter J. Hulick, (unknown)	7
8	A Quantitative Framework for Measuring Personalized Medicine Integration into US Healthcare Delivery Organizations 2021 ·Journal of Personalized Medicine ·(unknown), Daryl Pritchard, (unknown), (unknown), (unknown)	9
9	Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non–small-cell Lung Cancer 2020 ·Clinical Lung Cancer ·Apostolia M. Tsimberidou, Sheryl K. Elkin, (unknown), Daryl Pritchard	7
10	Cost-effectiveness of multi-gene panel sequencing (MGPS) for advanced non-small cell lung cancer (aNSCLC) patients. 2018 ·Journal of Clinical Oncology ·(unknown), Bernardo H. L. Goulart, Neal J. Meropol, Daryl Pritchard, Scott D. Ramsey	2
11	Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions 2018 ·Health Affairs ·Lincoln Nadauld, James M. Ford, Daryl Pritchard, Thomas D. Brown	22
12	Strategies for Integrating Personalized Medicine into Healthcare Practice 2017 ·Personalized Medicine ·Daryl Pritchard, (unknown), (unknown), (unknown), Catherine A. McCarty, Howard L. McLeod	79
13	What Contributes Most to High Health Care Costs? Health Care Spending in High Resource Patients 2016 ·Journal of Managed Care & Specialty Pharmacy ·Daryl Pritchard, Allison Petrilla, (unknown), Donald H. Taylor, Vernon F. Schabert, Robert W. Dubois	26
14	Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT) 2015 ·Journal of Managed Care & Specialty Pharmacy ·William J. Canestaro, Daryl Pritchard, Louis P. Garrison, Robert W. Dubois, David L. Veenstra	8
15	An Investigation into Sustainable Water Consumption in the University of British Columbia’s New Student Union Building Project 2011 ·Open Collections ·Daryl Pritchard, (unknown), Jingsheng Zhang	1
16	Today's Threat Is Tomorrow's Crisis: Advocating for Dental Education, Dental and Biomedical Research, and Oral Health 2006 ·Journal of Dental Education ·(unknown), (unknown), (unknown), (unknown), Daryl Pritchard, Richard W. Valachovic	6
17	Resistance to apoptosis, increased growth potential, and altered gene expression in cells that survived genotoxic hexavalent chromium [Cr(VI)] exposure 2005 ·Molecular and Cellular Biochemistry ·Daryl Pritchard, Susan Ceryak, Keri E. Ramsey, Travis J. O’Brien, Linan Ha, Jamie L. Fornsaglio, Dietrich Stephan, Steven R. Patierno	19
18	Fanconi anemia complementation group A cells are hypersensitive to chromium(VI)-induced toxicity. 2002 ·Environmental Health Perspectives ·(unknown), Travis J. O’Brien, Daryl Pritchard, Linan Ha, Susan Ceryak, Jamie L. Fornsaglio, Steven R. Patierno	18
19	Chromium(VI) Induces p53-Dependent Apoptosis in Diploid Human Lung and Mouse Dermal Fibroblasts 2000 ·Molecular Carcinogenesis ·Diane L. Carlisle, Daryl Pritchard, Jatinder Singh, Steven R. Patierno	81
20	Internalization of Carcinogenic Lead Chromate Particles by Cultured Normal Human Lung Epithelial Cells: Formation of Intracellular Lead-Inclusion Bodies and Induction of Apoptosis 1999 ·Toxicology and Applied Pharmacology ·Jatinder Singh, Daryl Pritchard, Diane L. Carlisle, John A. McLean, (unknown), Jan M. Orenstein, Steven R. Patierno	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact